Boston Talks: Real Conversations with Life Sciences Leaders
An entry point into the Richi Lifesciences program, this free virtual series introduces life sciences entrepreneurs to the perspectives, challenges, and breakthroughs shaping Boston’s innovation ecosystem—offering early inspiration before diving into the full immersion.
Boston Talks is an inspiring series of virtual fireside chats designed for life sciences entrepreneurs. Featuring insights from top VC partners and industry experts within the world’s largest life sciences ecosystem, these sessions offer valuable guidance on starting, funding, and scaling ventures. Attendees gain a glimpse into the dynamic conversations and expertise that define the Richi Lifesciences program.
Key Investment Terms for an Early Stage Healthcare VC Round
Corporate strategic investors: When to Include Them and What Precautions to Take
Alternate Funding Sources, Stretching Budgets, and Other Strategies to Extend Startup Capital
Life Sciences Startup Valuation: What to Use it For and How to Do It
Pitch Decks for Startups: What Impresses VCs and What Turns Them Off
Passing the Boards: How to Structure and Manage Boards of Directors and Advisors, and KOL Relationships
Planning your initial VC round: What do the VCs want to see?
The Angel Round: How to Attract and Close a Deal with Angels, Seed Capital Funds and Other Pre-VC Capital Sources
The Angel Round: How to Attract and Close a Deal with Angels, Seed Capital Funds and Other Pre-VC Capital Sources
SPEAKERS LINEUP
Donald B. Hawthorne | President at GTM® Hawthorne, Inc.
Geoff Pardo | General Partner at Gilde Healthcare Partners
Key Investment Terms for an Early Stage Healthcare VC Round
Shinichiro Fuse | Partner and Managing Director at TPG Life Sciences Innovation
Jeremy Sohn | Managing Partner at P74 Ventures
Life Sciences Startup Valuation: What to Use it For and How to Do It
Eric Langer | President & Managing Partner at BioPlan Associates, Inc.
Joseph McKneely | Partner at WilliamsMarston LLC
Planning your initial life sciences VC round: What do the VCs want to see?
Scott Rocklage | Founding Partner at 5AM Ventures
Dana Watt | Partner at Breakout Ventures
Corporate strategic investors in Life Sciences: When to Include Them and What Precautions to Take
Michael Baran | Executive Director at Pfizer Ventures
Ren Roome | Partner at Boston Millenia Partners
Meg Wood | Managing Director New York Blood Center Ventures
Pitch Decks for Life Sciences Startups: What Impresses VCs and What Turns Them Off
Jenny Rooke | Manager Director at Genoa Ventures
Neil Exter | Partner at Third Rock Ventures
The Angel Round: How to Attract and Close a Deal with Angels, Seed Capital Funds and Other Pre-VC Capital Sources
Henry Kay | Angel Investor at Boston Harbor Angels
Martha Farmer | Co-Founder & Board at Innoventure Labs
Ben Littauer | Angel Investor at TBD Angels
Alternate Funding Sources, Stretching Budgets, and Other Strategies to Extend Healthcare Startup Capital
David Michael | Managing Partner at Anzu Partners
Tiger Xie | Scientific Consultant at Eva Garland Consulting
Passing the Boards: How to Structure and Manage Boards of Directors and Advisors, and KOL Relationships
Ben Askew, Ph.D. | Partner at Xontogeny
Hits and Misses of Startup Slide Decks: What Impresses Investors, and What Turns Them Off
Hirak Parikh, Ph.D. | Principal Venture Investments at J&J Innovation
Russ Wilcox | Partner at Pillar VC
Raising Non-Dilutive Startup Capital from Government and Family Offices
Dr. Ethel Rubin | Entrepreneur in Residence at NIH SEED
Dr. Ruchi Dana | Partner and Executive Board Member at Dana Group
Passing the Boards: How to Structure and Manage Boards of Directors and Advisors, and KOL Relationships
Paul LaViolette | Managing Partner and COO at SV Health Investors
Hits and Misses of Startup Slide Decks: What Impresses Investors, and What Turns Them Off
Michael Greeley | Co-Founder and General Partner at Flare Capital Partners
Planning your First LS Institutional Capital Raise: How Much is Too Much?
Brian Goodman, Ph.D. | Principal at MPM Capital
Corporate Strategic Investors in LS: When to Include Them, and What Precautions to Take
Dr. Nandita Shangari | Managing Director at RA Capital
Creating a Winning Team to Attract Capital and Scale a Healthcare Startup
Lucio Ianone | Head of Venture Investments Health at Leaps by Bayer
Jessica A. Zeaske | Managing Partner at Echo Health Ventures
Planning your First LS Institutional Capital Raise: How Much is Too Much?
Shinichiro Fuse | Partner and Managing Director at TPG Life Sciences Innovation
Corporate Strategic Investors in LS: When to Include Them, and What Precautions to Take
Dr. Jeffrey Moore | President of MP Healthcare
Being There: How Much Does a Boston Location Matter in a post-COVID World?
Scott Rocklage | Founding Partner at 5AM Ventures
Creating a Winning Team to Attract Capital and Scale a LS Startup
Terry McGuire | Co-founder and Partner of Polaris Partners
Licensing LS Technology from Boston-area Universities – Tips, Traps and Tactics
Lesley Millar - Nicholson | Executive Director Technology Licensing Office, Office of Strategic Alliances & Technology Transfer at MIT